

PROVINCIAL FUNDING SUMMARY

Everolimus (Afinitor) for Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin (pCODR 10083)

pERC Recommendation: Recommends with conditions
For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: December 16, 2016

This information is current as of October 1, 2019.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Feb 1, 2018	<p>A) Well differentiated, non-functional, neuroendocrine tumours of gastrointestinal origin, unknown primary or other origins (except for lung - see below)</p> <ul style="list-style-type: none"> • Unresectable, locally advanced or metastatic disease • ECOG 0 - 2. • Adequate hematologic, renal and hepatic function. • Compassionate Access Program (CAP) approval granted by BC Cancer. <p>B) Well differentiated, non-functional, neuroendocrine tumours of lung origin</p> <ul style="list-style-type: none"> • Unresectable, locally advanced or metastatic disease • ECOG 0 - 2 • Adequate hematologic, renal and hepatic function • BC Cancer Compassionate Access Program (CAP) approval must be obtained
AB	Funded	Sept 4, 2018	<p>Everolimus for the treatment of unresectable, locally advanced or metastatic well-differentiated non-functional neuroendocrine tumours (NETs) of gastrointestinal or lung origin (GIL) in adults with documented radiological disease progression within six months and with a good performance status.</p>

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
SK	Funded	Oct 1, 2017	Treatment of unresectable, locally advanced or metastatic, well-differentiated, non functional neuroendocrine tumours (NETs) of gastrointestinal or lung origin (GIL) in adults with documented radiological disease progression within six months and with a good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity.
MB	Funded	Jan 28, 2018	For the treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of gastrointestinal or lung origin (GIL) in adults with documented radiological disease progression within six months and with a good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity.
ON	Funded	Nov 20, 2017	Initial: For the treatment of unresectable, locally advanced or metastatic, well-differentiated non functional neuroendocrine tumours (NETs) of gastrointestinal or lung origin (GIL) in adults with documented radiological disease progression within six months and with a good performance status (ECOG 0-2). Treatment should continue until confirmed disease progression or unacceptable toxicity. Renewal: The Patient's physician has confirmed that the Patient has benefited or continues to benefit from therapy with the Afinitor Product, as evidenced by no disease progression, and is expected to continue to do so.
NS	Under provincial consideration		
NB	Funded	Mar 20, 2018	For the treatment of patients with unresectable, locally advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors (NETs) of gastrointestinal or lung origin (GIL) with documented radiological disease progression within six months. Renewal Criteria: - Written confirmation that the patient has responded to treatment and there is no evidence of disease progression. Clinical Notes: 1. Patients must have a good performance status. 2. Treatment should be discontinued upon disease progression or unacceptable toxicity.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NL	Funded	Jul 29, 2019	AFINITOR (everolimus) is recommended for the treatment of unresectable, locally advanced or metastatic, well-differentiated nonfunctional neuroendocrine tumours (NETs) of gastrointestinal or lung origin (GIL) in adults with documented radiological disease progression within six months and with a good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity. Renewals will be considered for patients who do not have evidence of disease progression AND who have not developed unacceptable toxicities that require discontinuation of everolimus.
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.